Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
160
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists01:29

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

272
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
272
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids01:21

Chemotherapy-Induced Nausea and Vomiting: Cannabinoids

237
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
237
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

13.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
13.1K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Hypertension and brain damage: evidence from rodent models.

Laboratory animal research·2026
Same author

Mitochondria-Associated MicroRNAs: Emerging Roles in the Pathogenesis of Parkinson's Disease.

Biomedicines·2026
Same author

Next-Gen Stroke Models: The Promise of Assembloids and Organ-on-a-Chip Systems.

Cells·2025
Same author

Exploring the Antioxidant Roles of Cysteine and Selenocysteine in Cellular Aging and Redox Regulation.

Biomolecules·2025
Same author

Retinal Gatekeepers: Molecular Mechanism and Therapeutic Role of Cysteine and Selenocysteine.

Biomolecules·2025
Same author

The Inflammatory Bridge Between Type 2 Diabetes and Neurodegeneration: A Molecular Perspective.

International journal of molecular sciences·2025

相关实验视频

Updated: Jun 27, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K

在CIPN中分子和细胞参与.

Housem Kacem1, Annamaria Cimini1, Michele d'Angelo1

  • 1Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy.

Biomedicines
|April 27, 2024
PubMed
概括

化疗诱导的周围神经病变 (CIPN) 是抗癌药物的常见,令人衰弱的副作用. 本综述探讨了CIPN背后的复杂机制,并强调迫切需要有效的治疗方法.

科学领域:

  • 在瘤学瘤学.
  • 神经科学是一个神经科学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 化疗诱导的周围神经病变 (CIPN) 是各种抗癌药物的显著不良影响,包括税,化合物,类和蛋白酶体抑制剂.
  • CIPN表现为感觉,运动和自主神经功能障碍,导致疼痛,麻木,刺痛和虚弱等症状,严重影响患者的生活质量.

研究的目的:

  • 提供对CIPN当前理解的全面概述.
  • 阐明CIPN背后的复杂的生物和分子机制.
  • 确定CIPN研究的挑战和未来方向,包括生物标志物和治疗点的开发.

主要方法:

  • 文献评论专注于同行评审的文章和临床研究.
  • 对CIPN病理生理学当前知识的分析.
  • 综合有关影响CIPN的遗传,表观遗传和环境因素的信息.

主要成果:

  • CIPN是由直接的神经损伤,氧化应激,炎症,DNA损伤,微管功能障碍和改变的离子通道活性引起的.
  • 个人对CIPN的敏感性受到遗传,表观遗传和环境因素的组合的影响.
  • 目前对CIPN的管理策略主要是症状和息,没有普遍有效的治疗或预防措施.
关键词:
这些道是道.化学疗法 化疗 化疗这些机制的机制.神经炎症是一种神经炎症.神经病变是一种神经病变.

更多相关视频

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.5K

相关实验视频

Last Updated: Jun 27, 2025

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity
07:42

Nerve Excitability Assessment in Chemotherapy-induced Neurotoxicity

Published on: April 26, 2012

18.2K
Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment
04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

7.4K
Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1
09:39

Establishing a Mouse Model of a Pure Small Fiber Neuropathy with the Ultrapotent Agonist of Transient Receptor Potential Vanilloid Type 1

Published on: February 13, 2018

9.5K

结论:

  • 更深入地了解CIPN的细胞和分子机制对于开发有效的干预措施至关重要.
  • 对于新型生物标志物和治疗标来预防或治疗CIPN.有着至关重要的需求.
  • 需要进行进一步的研究,以解决癌症患者有效的CIPN管理的重大未满足需求.